Search Results - cancer+therapies

13 Results

Sort By:

Discovery of Well Defined Sulfated Glycopolymers as Specific Heparanase Inhibitors for Cancer Therapeutics

The remodeling of the extracellular matrix has been shown to be highly upregulated in cancer and inflammation and is critically linked to the processes of invasion and metastasis. The finding that heparanase is elevated in a wide variety of tumor types and is subsequently linked to the development of pathological processes has led to an explosion of...

Published: 12/2/2020 | Inventor(s): Hein Nguyen, Ravi Loka, Eric Sletten, Israel Vlodavsky

Keywords(s): Cancer, Cancer Therapies, Pharmaceuticals, Therapeutics

Category(s): Life Science, Oncology, Pharmaceuticals, Therapeutics

A method to induce ferroptosis and to downregulate androgen receptor/androgen receptor splice variant in prostate cancer cells

Prostate cancer (PCa) effects approximately three million men in the United States every year. About 10-20% of the cases of prostate cancer are castrate-resistant prostate cancer (CRPC). This form of PCa is highly resistant to what Is known as androgen depletion therapy and is often fatal. All types of PCa are sensitive to androgen receptor signaling...

Published: 11/19/2020 | Inventor(s): Zhihui Qin, Liping Xu

Keywords(s): Anti-cancer, Cancer, Cancer Therapies, Drug Delivery, Drug Target, Prostate Cancer

Category(s): Medical, Diseases, Drug Discovery, Pharmaceuticals, Oncology

Fc-folate conjugate for the treatment of triple negative breast cancer

Approximately 13% of women in the United States will develop breast cancer according to the American Cancer Society. That makes breast cancer the second leading cause of cancer death in women right behind lung cancer. Triple negative breast cancer (TNBC) represents about 10 – 20% of all breast cancers. Triple negative refers to cancer cells...

Published: 11/19/2020 | Inventor(s): Cecilia Speyer

Keywords(s): Anti-cancer, Breast Cancer, Cancer, Cancer Therapies

Category(s): Antibodies, Assays, Biology, Biomedical, Chemical Processing/Synthesis, Diseases, Drug Delivery, Life Science, Oncology, Protein/peptides, Receptors/targets, Small molecule, Therapeutics

An in vivo QQ-systemic protein delivery technology and applications

BackgroundThis invention contains a new composition of our researchers’ previously patented QQ-protein delivery technology and the in vivo applications of this protein delivery technology via systemic administered proteins for cancer diagnosis and therapy. Many proteins and peptides are used as highly specific and effective therapeutic agents....

Published: 8/3/2017 | Inventor(s): Jianjun Wang, Qianqian Li, Quan Jiang, Feng Jiang, Michael Chopp

Keywords(s): Cancer Therapies, Drug Delivery

Category(s): Diagnostics, Drug Delivery, Life Science, Oncology, Research tools, Therapeutics

A protein-induced In situ cell-conversion technology and applications

BackgroundCell reprogramming and trans-differentiation are techniques that convert somatic cells of individuals into either stem cells, including embryonic and adult stem cells (reprogramming) or the other type of somatic cells (trans-differentiation). These techniques are usually performed in the cell culture settings using viral gene delivery and...

Published: 8/3/2017 | Inventor(s): Jianjun Wang, Qianqian Li, Feng Jiang, Michael Chopp, Guojun Wu

Keywords(s): Cancer Therapies, Drug Delivery

Category(s): Drug Delivery, Life Science, Research tools, Oncology

ERK-Mediated Grb7 Phosphorylation: A Biomarker and Potential Therapeutic Target in Her2/Grb7 Amplified Cancers

This invention is a new bio-marker for breast and other cancers that have Her2 and Grb7 gene amplifications, thus providing a therapeutic intervention in Her2/Grb7 amplified cancers.Background40% of breast cancers, as well as several other cancer types, display increased activation of tyrosine kinases from the ErbB family, with Her2 found amplified...

Published: 8/3/2017 | Inventor(s): Guri Tzivion, Deborah Leicht, Alexander Kaplun, Stephen Ethier

Keywords(s): Biomarker, Biotechnology, Cancer, Cancer Therapies, Therapeutics

Category(s): Diagnostic, Life Science, Oncology

Modified Ectodomain of Human EGFR as a Potential Anticancer Agent

Development of a protein that attenuates EGFR and/or EGFR family members and is comprised of a modified EGFR ectodomain. The protein inhibits signaling via the EGFR and/or EGFR family members. The protein includes a portion of the EGFR (or EGFR family member) and the "U" region epitope of EGFR related protein (ERRP), wherein the portion of...

Published: 8/3/2017 | Inventor(s): Adhip Majumdar, Arun Rishi, Yingjie Yu

Keywords(s): Breast Cancer, Cancer, Cancer Therapies, Disease, Drug Target, Protein, Therapeutics

Category(s): Life Science, Biologicals, Diseases, Oncology

Translation Regulated (TR)-Mediated Gene Expression: Novel Expression and Reporter Vectors

Background: Often referred to as the crucial "drug discovery tool", cell based technology is one of the most significant sectors of pharmaceutical research and development. Of particular importance has been the development of information-rich cellular assays that determine drug candidate efficacy and safety (target identification, validation...

Published: 8/14/2013 | Inventor(s): Leon Carlock, Maria Cypher

Keywords(s): Animal Model, Anti-cancer, Cancer, Cancer risk, Cancer Therapies, Diagnostics, Imaging, Therapeutics

Category(s): Life Science, Diagnostics, Research tools, Assays, Cell lines, Oncology

Dual action nanocarrier combining CXCR4 antagonist and polyplex gene delivery for treatment of metastatic cancer and other diseases

Novel bio-reducible polymer compositions which combine the ability to act as a CXCR4 antagonist and simultaneously provide enhanced gene delivery through the formation of inert nanocarrier polyplexes have been developed. As would be expected for biodegradable polymers, the cytotoxicity of these nanocarrier compositions are very low with measured IC50...

Published: 9/10/2012 | Inventor(s): David Oupicky, Jing Li

Keywords(s): Cancer, Cancer Therapies, Compound, Drug Delivery, Drug Target, Formulation, Imaging, Nanomaterials, Pharmaceuticals, Therapeutics

Category(s): Drug Delivery, Gene Therapy, Therapeutics, Life Science, Oncology, Nano-based, Metabolic disorders, Biologicals

GlyB4 Fusion with Neuregulin Heparin-Targeting Domain to Block Neuregulin Signaling

We have harnessed this natural targeting ability of NRG by fusing the HBD of NRG to soluble HER4. This fusion protein retains high affinity heparin binding to heparin and to cells that express heparan sulfates resulting in a more potent NRG antagonist. In vivo, it is targeted to peripheral nerve segments where it blocks the activity of NRG as a Schwann...

Published: 5/16/2011 | Inventor(s): Jeffrey Loeb, Qunfang Lee

Keywords(s): Anti-cancer, Biotechnology, Cancer risk, Cancer Therapies, Drug Delivery, Drug Target, Epilepsy

Category(s): Life Science, Drug Delivery, Other

1 2